Servier Secures Day One Biopharma with 85.34% Tender, Initiates Nasdaq Delisting

Servier completed its acquisition of Day One Biopharmaceuticals on April 23, 2026, finalizing a strategic move for the global pharmaceutical group. This action follows a successful tender offer that concluded the previous day, officially integrating Day One into Servier's portfolio.

The tender offer saw 88,180,910 shares of Day One Biopharmaceuticals submitted, representing 85.34% of the company's total outstanding shares. This acceptance rate allowed the merger to proceed on April 23, 2026, utilizing a Section 251(h) short-form merger. This legal provision enables mergers without a full shareholder vote when a high percentage of shares are already acquired, streamlining the process. Day One Biopharmaceuticals is now a wholly owned subsidiary of Servier.

Following the acquisition, Servier requested Day One's delisting from Nasdaq through a Form 25 filing. The company also plans to file Form 15 with the U.S. Securities and Exchange Commission (SEC) to suspend Day One's public reporting obligations.

The delisting means Day One Biopharmaceuticals shares will no longer trade on the Nasdaq stock exchange, effectively removing the company from public market access and its status as a publicly traded entity. Suspending reporting obligations, via the upcoming Form 15 filing, will remove the requirement for Day One to file regular financial statements and disclosures with the SEC. This change shifts its transparency from public filings to internal disclosures as a privately held subsidiary under Servier's direct control. Shareholders who did not tender their shares had them converted into the offer price at the merger's effective time, concluding their investment in the publicly traded company.

Industry observers will monitor how this integration impacts Servier's market position and future pharmaceutical development pipelines.